Yamagata, Kaoru
Nakayamada, Shingo
Tanaka, Yoshiya
Funding for this research was provided by:
Ministry of Health, Labour and Welfare
the Ministry of Education, Culture, Sports, Science and Technology of Japan
Japan Agency for Medical Research and Development
the University of Occupational and Environmental Health, Japan,
Article History
Received: 21 April 2020
Accepted: 8 June 2020
First Online: 3 August 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Y. Tanaka has received consulting fees, speaking fees, and/or honoraria from Daiichi-Sankyo, Astellas, Pfizer, Mitsubishi-Tanabe, Bristol-Myers, Chugai, YL Biologics, Eli Lilly, Sanofi, Janssen, and UCB, and has received research grants from Mitsubishi-Tanabe, Takeda, Bristol-Myers, Chugai, Astellas, Abbvie, MSD, Daiichi-Sankyo, Pfizer, Kyowa-Kirin, Eisai, and Ono. S. Nakayamada has received consulting fees, speaking fees, and/or honoraria from Bristol-Myers, Pfizer, Chugai, Astellas, Sanofi, GlaxoSmithKline, and Asahi-kasei, and has received research grants from Mitsubishi-Tanabe, Takeda, Novartis, and MSD. K. Yamagata declares no conflict of interest.